Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman
Ghent, Belgium – August 29, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors. Mr. Weinand brings with him a wealth of experience with more than 35 years in the pharmaceutical industry and […]
Read Post
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
• Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled antibody discovery technologies on two GPCR targets • Confo to receive upfront and milestone payments • Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – June 15, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting […]
Read Post
Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy
US trial with leriglitazone to commence in mid-2023 providing an FDA-approved route to US market whilst EMA evaluates European Marketing Authorization Application (MAA) Mataró, Barcelona, Spain, May 31, 2023 – Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces the US Food […]
Read Post
Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
– CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile – Positive results from the study to date support preparations for a registrational trial for CTx-PDE6b in PDE6b Retinitis Pigmentosa – Regulatory approval received to expand the current study to include younger patients with earlier stages […]
Read Post
ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors
• Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors. Dr. Pamela […]
Read Post
Indigo Appoints Dr. Arun Venkatasubramanian as Chief Technology Officer
Arun is an award-winning engineer who brings over 15 years’ experience in leading the design and development of transformational technology within the medical, consumer, and military sectors BELGIUM – Ghent, 15 May 2023 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of a Continuous Metabolite Monitoring (CMM™) device for people living with […]
Read Post
Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)
Initial evidence of disease stabilization was demonstrated for all patients using radiological, clinical and plasma biomarker assessments at 6 months (24 weeks) of treatment Mataró, Barcelona, Spain, April 25, 2023 – Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces 24-week interim […]
Read Post
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Companies join forces bringing together Bristol Myers Squibb’s (BMS) deep oncology and clinical development expertise and Tubulis’ differentiated and unique approach to Antibody-Drug- Conjugate (ADC) design with the goal of delivering the true therapeutic potential of ADCs Tubulis to receive upfront payment of $22.75 million and milestone payments potentially totaling over $1 billion plus tiered […]
Read Post
Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled technologies for fragment- and structure-based drug design Confo to receive upfront and milestone payments totaling EUR 168M Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – March 30, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting […]
Read Post
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19.
ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike Focus on protecting the millions of immuno-compromised patients, who are most vulnerable to COVID-19 Ghent, Belgium, 13 March 2023: ExeVir Bio, a biotech company developing robust single domain antibody therapies for broad […]
Read Post
Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554
Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if Lilly proceeds with a second product candidate Tiered royalties payable to Confo on net sales Confo to have a co-investment option Ghent, Belgium – March 2, 2023 – Confo Therapeutics, a leader in the discovery […]
Read Post
Cellaion SA announces a total fundraising of EUR 23 million in 2022 for its phase IIB study in Acute on Chronic Liver Failure with Truffle Capital as lead investor in the final Closing followed by Newton Biocapital, Wallonie Entreprendre and individual investors.
Mont-Saint-Guibert, Belgium, 2023/01/13. Cellaïon is a biotechnology company based in Mont-St-Guibert, active in the field of cell therapy, an area of excellence in the life sciences industry in Wallonia. Its flagship product HepaStem®, in advanced clinical development, targets severe liver diseases, and in particular Acute on Chronic Liver Failure (ACLF). ACLF is an acute hepatic […]
Read Post
TargED Biopharmaceuticals announces the appointment of Erik van den Berg as Chair of its Supervisory Board
Utrecht, the Netherlands, January 19, 2023. TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, announced today the appointment of Erik van den Berg as Chair and independent Board Member of its Supervisory Board. Erik holds a Master’s degree in Chemistry from the University of Utrecht, the Netherlands, and a MBA from Manchester […]
Read Post
Belgium: ExeVir lands European venture debt financing to develop novel nanobody COVID-19 therapy
ExeVir signs €25 million venture debt financing with European Investment Bank to develop a llama-derived nanobody COVID-19 therapeutic, labelled XVR012. Project expected to have important public health impact, addressing underserved therapeutics market for immunocompromised and elderly people. Venture debt financing is part of EIB’s COVID-19 response and is guaranteed by the InnovFin programme under the EU’s […]
Read Post
Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer
Mont Saint-Guibert, Belgium – December 27, 2022 – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, today announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company. Dr. Ashworth brings deep experience and strong managerial […]
Read Post
Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma
Study results demonstrate NVD-003 has a favorable safety profile and convincing efficacy including rapid, durable bone healing in patients following failure of conventional treatment Clinical data will inform development of the Company’s autologous and allogeneic therapeutics for critical size bone defects and common orthopedic conditions First patient enrolled in Phase 1b/2a US/EU clinical trial in […]
Read Post
Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe9
The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD) Mataró, Barcelona (Spain) and Düsseldorf (Germany), November 10, 2022 – Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders and the […]
Read Post
Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million
Funding will support development of next generation orthopedic products that provide accelerated healing through single treatment cures Equity Funding led by CR-CP Life Science Fund, New Science Ventures, Fund+ and SRIW MONT SAINT-GUIBERT, BELGIUM – November 3, 2022 – Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative […]
Read Post
Coave Therapeutics Strengthens Board of Directors
Paris, France, October 20th, 2022 – Coave Therapeutics (‘Coave’), a biotech company leading the transition of genetic medicine from (ultra) rare to prevalent conditions in neurodegenerative diseases, today announces Frederic Chereau as Chairman of the Board and the appointment of Dr Claudia Mitchell, PhD, MBA to the Company’s Board of Directors as an independent non-executive […]
Read Post
ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors
Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 variants of concern by end 2022 Triple mode of action dengue fever program identified for development Industry veteran with exceptional leadership experience to support ExeVir’s new progressive pipeline against infectious diseases Ghent, Belgium, 20 Oct 2022: ExeVir is developing robust therapies providing broad protection […]
Read Post
Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial
BELGIUM – Ghent, September 29, 2022 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigo’s continuous multi-metabolite (‘CMM’) device. Indigo’s subcutaneously inserted CMM […]
Read Post
AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development
• Emmanuel Hanon, PhD, will chair the company’s scientific advisory board. • Professor Peter Piot {MD, PhD) and Professor Patrick Soentjens {MD, PhD) have been appointed as advisors. • Together, they bring complementary expertise in infectious diseases, vaccines, and global health management as well as over 80 years of combined experience. Leuven, Belgium, 24 March […]
Read Post
Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders
Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders Paris, France, September 14, 2022 – Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces it has entered into […]
Read Post
Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD
Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD) Mataró, Barcelona, Spain, September 14, 2022 – Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders, today announces that it has filed a Marketing Authorization Application (MAA) […]
Read Post
KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform
KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs linked to Belgium-based university KU Leuven. The funding round was led by V-Bio Ventures and Fund+. The other investors are Flanders Future TechFund, Thuja […]
Read Post